{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hui D"],"funding":["NINR NIH HHS","National Cancer Institute","NCI NIH HHS","National Institutes of Health","Andrew Sabin Family Fellowship Award"],"pagination":["e883-e892"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8100563"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(5)"],"pubmed_abstract":["<h4>Background</h4>The effect of high-flow oxygen (HFOx) and high-flow air (HFAir) on dyspnea in nonhypoxemic patients is not known. We assessed the effect of HFOx, HFAir, low-flow oxygen (LFOx), and low-flow air (LFAir) on dyspnea.<h4>Subjects, materials, and methods</h4>This double-blind, 4×4 crossover clinical trial enrolled hospitalized patients with cancer who were dyspneic at rest and nonhypoxemic (oxygen saturation >90% on room air). Patients were randomized to 10 minutes of HFOx, HFAir, LFOx, and LFAir in different orders. The flow rate was titrated between 20-60 L/minute in the high-flow interventions and 2 L/minute in the low-flow interventions. The primary outcome was dyspnea numeric rating scale (NRS) \"now\" where 0 = none and 10 = worst.<h4>Results</h4>Seventeen patients (mean "],"journal":["The oncologist"],"pubmed_title":["High-Flow Oxygen and High-Flow Air for Dyspnea in Hospitalized Patients with Cancer: A Pilot Crossover Randomized Clinical Trial."],"pmcid":["PMC8100563"],"funding_grant_id":["P30CA016672","P30 CA016672","R21 NR016736","1R01CA214960-01A1","R01 CA225701","R01 CA214960"],"pubmed_authors":["Hernandez F","Elsayem A","Thomas S","Lu Z","Bruera E","Hui D","Urbauer D"],"additional_accession":[]},"is_claimable":false,"name":"High-Flow Oxygen and High-Flow Air for Dyspnea in Hospitalized Patients with Cancer: A Pilot Crossover Randomized Clinical Trial.","description":"<h4>Background</h4>The effect of high-flow oxygen (HFOx) and high-flow air (HFAir) on dyspnea in nonhypoxemic patients is not known. We assessed the effect of HFOx, HFAir, low-flow oxygen (LFOx), and low-flow air (LFAir) on dyspnea.<h4>Subjects, materials, and methods</h4>This double-blind, 4×4 crossover clinical trial enrolled hospitalized patients with cancer who were dyspneic at rest and nonhypoxemic (oxygen saturation >90% on room air). Patients were randomized to 10 minutes of HFOx, HFAir, LFOx, and LFAir in different orders. The flow rate was titrated between 20-60 L/minute in the high-flow interventions and 2 L/minute in the low-flow interventions. The primary outcome was dyspnea numeric rating scale (NRS) \"now\" where 0 = none and 10 = worst.<h4>Results</h4>Seventeen patients (mean ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-26T20:06:19.114Z","creation":"2022-02-10T09:56:06.271Z"},"accession":"S-EPMC8100563","cross_references":{"pubmed":["33289276"],"doi":["10.1002/onco.13622"]}}